PALI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Palisade Bio Inc (PALI) is not a strong buy for a beginner, long-term investor at this time. The technical indicators show some bullish momentum, but the lack of positive financial performance, absence of proprietary trading signals, and a negative short-term stock trend outweigh the positive analyst ratings. Given the investor's preference for long-term growth, it would be prudent to wait for stronger financial results or clearer catalysts before committing to this stock.
The MACD histogram is positive and expanding, indicating bullish momentum. The RSI is neutral at 66.598, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 1.879 and 1.967, while support levels are at 1.597 and 1.509. However, the stock trend analysis suggests a 90% chance of a -0.2% drop in the next day, -2.82% in the next week, and -4.82% in the next month, which indicates a bearish short-term outlook.
Analysts have given strong buy ratings with high price targets ranging from $5 to $25, citing the company's lead drug PALI-2108 as a promising treatment for inflammatory bowel diseases. The drug has shown compelling clinical results, including 100% clinical response and 40% clinical remission in ulcerative colitis trials. Upcoming Phase 1b data for fibrostenotic Crohn's disease in Q1 could act as a catalyst.
There is no significant hedge fund or insider trading activity, and the stock trend analysis predicts a bearish short-term performance. Additionally, there are no recent congress trading data or proprietary trading signals to support a buy decision.
In Q3 2025, Palisade Bio reported no revenue growth (0% YoY) and a net income loss of -$2,868,000, down -17.75% YoY. EPS declined significantly by -83.62% YoY to -0.38. Gross margin remains at 0, indicating no profitability.
Analysts have initiated coverage with strong buy ratings and high price targets ($5 to $25). They highlight the potential of PALI-2108 in treating inflammatory bowel diseases, with promising clinical results and upcoming pipeline catalysts. However, these ratings are speculative and contingent on future clinical trial outcomes.
